A Swiss Cancer Research grant to Prof. Francesco Bertoni

news on 22 Jul , 2019
Prof. Francesco Bertoni has received a three-years financial support to study the mechanism of resistance to the combination of copanlisib and venetoclax in marginal zone lymphomas. The project, with PD Anastasios Stathis and Prof. Andrea Alimonti as co-applicants, follows the design of the phase I study SAKK 66/18 (NCT03886649). The trial has indeed just opened the recruitment and is based on Pro...

New review article from Catapano and Carbone groups

news on 2 Jul , 2019
New review article from Catapano and Carbone groups focusing on transcriptional reprogramming in cancer stem cells. In this article, the authors evaluate the role of prostate cancer stem cells in disease progression and treatment resistance and the impact of transcriptional regulators on stemness-associated phenotypic reprogramming. Recent progress in this area supports the possibility of interfe...

15-ICML International Conference on Malignant Lymphoma

news on 30 Jun , 2019
Take a look at the healthbook 15-ICML Newsroom featuring video interviews with renowned experts in the fields of haematology/oncology and a selection of clinically relevant study highlights of the 15th International Conference on Malignant Lymphoma(15-ICML). https://healthbook.ch/oncology-hematology/news/15-icml-2019-newsroom/?access_code=5123b056f147a2aa9c50c082d76c7542

New review article by Prof. Francesco Bertoni on BET inhibitors

news on 17 Jun , 2019
Prof. Francesco Bertoni and his Colleague PD Anastasios Stathis of the Oncology Institute of Southern Switzerland (IOSI) has just been published a review article that summarizes the current knowledge on BET inhibitors in lymphomas. The article is based on the talk given at the 2018 “Inaugural AACR International Meeting Advances in Malignant Lymphoma”, a conference organized in cooperation with the...

Cancer research: IOR receives important grant

news on 12 Jun , 2019
Proteins in cells are subject to various chemical modifications that regulate their activity. One common modification consists in the attachment of ubiquitin molecules through a cascade of enzymes. Genetic defects in this ubiquitin cascade are the cause of many acquired and hereditary diseases, including neurodegenerative, immune and tumour disorders. Due to the complex biology and transient natur...